Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3
January 10, 2025 08:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
GLP-1 Medications Fuel Growth in Medical Aesthetics, with Weight Loss Accounting for 11% of Non-Surgical Spending in 2024
January 09, 2025 09:00 ET
|
Guidepoint Qsight
GLP-1 medications drove 13% of non-surgical aesthetic spend in 2024, reshaping the $19.2B industry as medspas see rising revenue and younger patients.
Kailera Therapeutics Appoints Laurie Stelzer as Chief Financial Officer
January 08, 2025 08:05 ET
|
Kailera Therapeutics, Inc.
Kailera Therapeutics today announced the appointment of Laurie Stelzer as Chief Financial Officer.
Kailera Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025 08:15 ET
|
Kailera Therapeutics, Inc.
Ron Renaud, Kailera's President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025.
CORXEL Acquires Worldwide (excluding Greater China) Rights to an Oral Small Molecule GLP-1 RA for the Treatment of Obesity and Diabetes
December 23, 2024 08:01 ET
|
Corxel Pharmaceuticals
CORXEL expands its cardiometabolic pipeline into obesity and diabetes.
B&D Nutritional Ingredients Announces New Customer Product Launch—A Nutritional Supplement System Supporting GLP-1 Medication Users
December 04, 2024 09:00 ET
|
B&D Nutritional Ingredients
NUTRILINQ™ is a physician-formulated nutritional system touted as the first science-backed nutritional support system for GLP-1 medication users.
Kailera Therapeutics Appoints Scott M. Akamine as Chief Legal Officer
November 12, 2024 08:00 ET
|
Kailera Therapeutics, Inc.
Today, Kailera Therapeutics announced the appointment of Scott Akamine as Chief Legal Officer.
Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data
November 01, 2024 13:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study
October 30, 2024 08:30 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Evoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI®
October 28, 2024 07:00 ET
|
Evoke Pharma, Inc.
Analysis of real-world data compared patients on GIMOTI (n=51) to Oral Metoclopramide (n=41), both taking GLP-1s, showing significant statistical improvement for GIMOTI over Oral Metoclopramide in All...